Key Points
- CEO Seth Lederman's insider purchase: Lederman bought 15,000 shares at an average price of $14.89 on March 18 (≈$223,350), raising his holding to 15,001 shares, a sizable insider buy disclosed in an SEC filing that can signal management confidence.
- Mixed Q4 results and large losses: Tonix reported a revenue beat ($5.39M vs. $2.97M expected) but a bigger-than-expected EPS loss (‑$3.98 vs. ‑$3.16), with extremely negative margins and analysts forecasting substantial FY losses, indicating ongoing profitability pressure.
- Market and analyst backdrop: Institutional ownership is high (≈82.3%), analyst ratings are mixed (consensus "Hold" with two Buys and one Sell) and the stock is volatile—trading well below its 1‑year high despite a consensus price target near $70.
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Get Free Report) CEO Seth Lederman acquired 15,000 shares of the business's stock in a transaction on Wednesday, March 18th. The shares were purchased at an average price of $14.89 per share, with a total value of $223,350.00. Following the completion of the purchase, the chief executive officer owned 15,001 shares in the company, valued at $223,364.89. This represents a 1,500,000.00% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website.
Tonix Pharmaceuticals Price Performance
NASDAQ TNXP opened at $14.19 on Thursday. The stock's 50 day simple moving average is $15.58 and its 200-day simple moving average is $18.57. The company has a market cap of $190.15 million, a PE ratio of -0.99 and a beta of 1.88. Tonix Pharmaceuticals Holding Corp. has a 1-year low of $13.07 and a 1-year high of $69.97.
Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last issued its quarterly earnings results on Thursday, March 12th. The company reported ($3.98) EPS for the quarter, missing the consensus estimate of ($3.16) by ($0.82). The firm had revenue of $5.39 million for the quarter, compared to analysts' expectations of $2.97 million. Tonix Pharmaceuticals had a negative return on equity of 60.15% and a negative net margin of 946.22%. On average, equities research analysts anticipate that Tonix Pharmaceuticals Holding Corp. will post -1762.5 EPS for the current fiscal year.
Analyst Ratings Changes
A number of equities analysts recently weighed in on the stock. Wall Street Zen raised shares of Tonix Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday, January 17th. Weiss Ratings reissued a "sell (e+)" rating on shares of Tonix Pharmaceuticals in a research note on Wednesday, January 21st. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, Tonix Pharmaceuticals presently has an average rating of "Hold" and a consensus price target of $70.00.
Get Our Latest Stock Report on TNXP
Trending Headlines about Tonix Pharmaceuticals
Here are the key news stories impacting Tonix Pharmaceuticals this week:
- Positive Sentiment: CEO Seth Lederman purchased 15,000 shares at about $14.89, a sizable insider buy that can be read as management confidence in the company’s outlook. SEC Form 4 - Lederman Insider Purchase
- Positive Sentiment: Tonix will present at BIO-Europe Spring (Mar 24); investor presentations at major partnering conferences can boost visibility for business development and licensing opportunities. Tonix to Present at BIO-Europe Spring 2026
- Positive Sentiment: Tonix announced an oral presentation and two posters on its preclinical immuno‑oncology portfolio at AACR 2026 (April). Early scientific data and conference exposure could advance partnerships or pipeline value if findings are viewed favorably. Tonix AACR Presentations
- Neutral Sentiment: Q4 results showed a revenue beat but an EPS miss, a mixed read that suggests commercial traction but ongoing profitability and margin pressure; investors may focus on upcoming guidance and cash runway details. Tonix Q4: Revenue Beat, EPS Miss
- Negative Sentiment: Noble Financial revised estimates: it cut FY2026 and some quarterly EPS forecasts (notably Q3/Q4), increasing the large year‑over‑year loss outlook—this analyst downgrade pressure likely weighs on sentiment and share price. MarketBeat - Noble Financial Estimate Changes
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently modified their holdings of TNXP. Vanguard Group Inc. increased its position in Tonix Pharmaceuticals by 238.1% during the third quarter. Vanguard Group Inc. now owns 556,957 shares of the company's stock worth $13,456,000 after purchasing an additional 392,225 shares during the last quarter. Balyasny Asset Management L.P. acquired a new position in Tonix Pharmaceuticals in the 4th quarter valued at about $2,895,000. Geode Capital Management LLC grew its stake in shares of Tonix Pharmaceuticals by 182.4% in the 2nd quarter. Geode Capital Management LLC now owns 175,212 shares of the company's stock valued at $6,305,000 after buying an additional 113,175 shares during the period. Nuveen LLC grew its stake in shares of Tonix Pharmaceuticals by 507.7% in the 4th quarter. Nuveen LLC now owns 93,402 shares of the company's stock valued at $1,459,000 after buying an additional 78,033 shares during the period. Finally, Capital Fund Management S.A. acquired a new stake in shares of Tonix Pharmaceuticals during the 3rd quarter worth approximately $1,521,000. Institutional investors and hedge funds own 82.26% of the company's stock.
Tonix Pharmaceuticals Company Profile
(
Get Free Report)
Tonix Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapeutics for central nervous system disorders, immunology and rare diseases. The company's pipeline includes small-molecule and biologic product candidates designed to address conditions such as fibromyalgia, post-traumatic stress disorder (PTSD) and other chronic pain syndromes, as well as vaccines for potential viral and biothreat agents.
Among Tonix's lead programs is TNX-102 SL, a sublingual formulation of cyclobenzaprine being evaluated for the treatment of fibromyalgia and PTSD.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
